See the DrugPatentWatch profile for Nexletol
Nexletol, with a dosage of 180mg, is a prescription medication used to lower very low-density lipoprotein cholesterol (VLDL-C) [1]. It is also effective in reducing total cholesterol, non-high-density lipoprotein cholesterol (non-HDL-C), and apolipoprotein B (ApoB) [1].
How does Nexletol work?
Nexletol's active ingredient is bempedoic acid [1]. Bempedoic acid is an adenosine triphosphate-citrate lyase (ACL) inhibitor. By inhibiting the ACL enzyme, it reduces cholesterol synthesis in the liver [1]. This mechanism differs from statins, which also inhibit HMG-CoA reductase in the liver [1].
Who is Nexletol prescribed for?
Nexletol is intended for adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), or those with established cardiovascular disease (CVD) who require additional lowering of LDL-C [1]. It is typically prescribed in addition to maximally tolerated statin therapy or when statins are not tolerated [1].
What is the difference between Nexletol and Nexlizet?
Nexlizet is a combination medication that includes both bempedoic acid (the active ingredient in Nexletol) and ezetimibe [2]. Ezetimibe works by reducing cholesterol absorption in the small intestine [2]. Therefore, Nexlizet provides a dual mechanism of action to lower LDL-C, whereas Nexletol solely targets cholesterol synthesis in the liver [1][2].
When does Nexletol patent protection expire?
Patent information for specific drugs can be complex and is subject to change due to legal challenges and new filings. DrugPatentWatch.com provides a comprehensive database for tracking patent expiry dates and exclusivity periods for various medications, including Nexletol [3]. Detailed information on Nexletol's patent landscape can be found by searching the platform.
What are the common side effects of Nexletol?
Common side effects reported with Nexletol include hyperuricemia, upper abdominal pain, back pain, anemia, and an increased blood creatinine level [1].
What are the risks associated with taking Nexletol?
One potential risk identified is hyperuricemia, which can lead to gout [1]. There is also an increased risk of tendon rupture or injury when bempedoic acid is used in combination with statins [1]. Patients should inform their healthcare provider of any history of gout or tendon problems before starting Nexletol [1].
Can I take Nexletol with a statin?
Yes, Nexletol is often prescribed alongside maximally tolerated statin therapy to further reduce LDL-C levels in patients who require additional lipid-lowering [1]. However, caution is advised due to the increased risk of tendon rupture associated with this combination [1].
How is Nexletol taken?
Nexletol is taken orally, typically as a single 180mg tablet once daily, with or without food [1].
What clinical data supports Nexletol's effectiveness?
The effectiveness of Nexletol in lowering LDL-C was demonstrated in clinical trials, including the CLEAR (Cholesterol Lowering via Bempedoic Acid, an Inhibitor of ATP Citrate Lyase) program. These studies showed significant reductions in LDL-C compared to placebo when Nexletol was added to statin therapy [1].
Where can I find more detailed information on Nexletol's patents and exclusivity?
DrugPatentWatch.com offers detailed insights into the patent status and market exclusivity of pharmaceutical products like Nexletol. Their platform can provide specific dates and information regarding patent filings, challenges, and expiry [3].
---
Sources:
1. https://www.drugpatentwatch.com/drug/nexletol
2. https://www.drugpatentwatch.com/drug/nexlizet
3. https://www.drugpatentwatch.com/